Loading

Cell View

Cell Information

  lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)

Overall DesignA total of 221 single candidate prostate CTCs were isolated from 18 patients with metastatic prostate cancer and 4 patients with localized prostate cancer. Of these, 133 cells (60%) had RNA of sufficient quality for amplification and next generation RNA sequencing, and 122 (55%) had >100,000 uniquely aligned sequencing reads. In addition to candidate CTCs, we also obtained comprehensive transcriptomes for 12 bulk primary prostate cancers (macrodissected for >70% tumor content), 30 single cells derived from four different prostate cancer cell lines, and 5 patient-derived leukocyte controls. The leukocytes were readily distinguished by their expression of hematopoietic lineage markers and served to exclude any CTCs with potentially contaminating signals. Strict expression thresholds were used to define lineage-confirmed CTCs, scored by prostate lineage-specific genes (PSA, PSMA, AMACR, AR) and standard epithelial markers (KRT7, KRT8, KRT18, KRT19, EpCAM). 28 cells were excluded given the presence of leukocyte transcripts suggestive of cellular contamination or misidentification during selection, and 17 cells were excluded given low expression of both prostate lineage-specific genes and 5 standard epithelial markers. The remaining 77 cells, defined as lineage-confirmed CTCs, displayed expression of either prostate lineage-specific or epithelial genes, and low expression of leukocyte-specific genes, consistent with their tumor of origin.
SummaryProstate cancer is initially responsive to androgen deprivation, but the effectiveness of androgen receptor (AR) inhibitors in recurrent disease is variable. Biopsy of bone metastases is challenging, hence sampling circulating tumor cells (CTCs) may reveal drug resistance mechanisms. We established single cell RNA-sequencing profiles of 77 intact CTCs isolated from 13 patients (mean 6 CTCs/patient) using microfluidic enrichment. Single CTCs from each individual display considerable heterogeneity, including expression of AR gene mutations and splicing variants. Retrospective analysis of CTCs from patients progressing on AR inhibitor, compared with untreated cases indicates activation of noncanonical Wnt signaling (P=0.0064). Ectopic expression of Wnt5a in prostate cancer cells attenuates the antiproliferative effect of AR inhibition, while its suppression in drug-resistant cells restores partial sensitivity, a correlation also evident in an established mouse model. Thus, single cell analysis of prostate CTCs reveals heterogeneity in signaling pathways that could contribute to treatment failure.
Dataset viewGSE67980
PMID26383955

Samples in lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)

Displaying 1-10 of 36 results.
SeriesSampleInstrumentOrganismTitleCell Source
GSE67980GSM1660155AB 5500xl Genetic AnalyzerHomo sapiensPr18.1.1lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)
GSE67980GSM1660156AB 5500xl Genetic AnalyzerHomo sapiensPr18.1.4lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)
GSE67980GSM1660157AB 5500xl Genetic AnalyzerHomo sapiensPr18.1.5lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)
GSE67980GSM1660158AB 5500xl Genetic AnalyzerHomo sapiensPr18.1.6lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)
GSE67980GSM1660159AB 5500xl Genetic AnalyzerHomo sapiensPr18.1.7lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)
GSE67980GSM1660160AB 5500xl Genetic AnalyzerHomo sapiensPr18.1.8lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)
GSE67980GSM1660161AB 5500xl Genetic AnalyzerHomo sapiensPr18.2.1lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)
GSE67980GSM1660162AB 5500xl Genetic AnalyzerHomo sapiensPr18.2.2lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)
GSE67980GSM1660163AB 5500xl Genetic AnalyzerHomo sapiensPr18.2.3lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)
GSE67980GSM1660164AB 5500xl Genetic AnalyzerHomo sapiensPr19.1.2lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)

Gene rank in lineage-confirmed PCa CTC CRPC progressed on enzalutamide (Group B)

Displaying 31-40 of 18557 results.
Rank orderGene SymbolEnsembl ID
31NACAENSG00000196531
32RPL10ENSG00000147403
33RPL31ENSG00000071082
34RPSAENSG00000168028
35FTH1ENSG00000167996
36TPT1ENSG00000133112
37NEAT1ENSG00000245532
38RPS10ENSG00000124614
39ATP5BENSG00000110955
40RPS14ENSG00000164587